News & Updates

Clindamycin delivers in bacterial vaginosis
Clindamycin delivers in bacterial vaginosis
29 Apr 2023

Use of a single dose of a new bioadhesive 2% clindamycin vaginal gel in the treatment of bacterial vaginosis appears to result in a rapid resolution of symptoms, with high acceptability among women, as reported in a study.

Clindamycin delivers in bacterial vaginosis
29 Apr 2023
Tralokinumab a promising treatment option in young people with moderate-to-severe AD
Tralokinumab a promising treatment option in young people with moderate-to-severe AD
29 Apr 2023
Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
27 Apr 2023 byAudrey Abella

In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.

Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
27 Apr 2023
Bivalent mRNA-1273.214 booster offers superior immunogenicity vs original vax
Bivalent mRNA-1273.214 booster offers superior immunogenicity vs original vax
27 Apr 2023
Which factors improve survival in ICI-treated patients with NSCLC?
Which factors improve survival in ICI-treated patients with NSCLC?
25 Apr 2023

The survival benefit derived from using immune checkpoint inhibitors (ICIs) is more evident in patients with advanced nonsmall cell lung cancer (NSCLC) who received first-line therapy, showed low neutrophil/lymphocyte ratio (NLR), and had no history of hormone use following initial treatment, suggests a recent study.

Which factors improve survival in ICI-treated patients with NSCLC?
25 Apr 2023